Nucleophosmin (NPM1) is a nucleocytoplasmic shuttling protein, which is mutated in approximately 30% of acute myeloid leukemia (AML). 1 In leukemia, mutations are typically found in exon 12 of the NPM1 gene, leading to ectopic cytoplasmic expression of the protein (normally found in the nucleolus) due to changes of two crucial C-terminal tryptophan(s) and generation of a novel nuclear export signal. 2, 3 The aberrant nuclear export of the NPM1 protein and its accumulation in the cytoplasm is detectable by immunohistochemistry. [2] [3] [4] Because of its distinctive biological, clinical and prognostic features 5, 6 'AML with mutated NPM1' has been included as a provisional entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues. 7 Of importance, AML with NPM1 mutations but without FLT3-ITD seem to benefit from a new upfront therapy concept including all-trans retinoic acid evaluated for elderly patients 8 and recently under investigation in AML patients under the age of 60.
NPM1 mutations can be detected on the molecular level using direct sequencing, high-resolution fragment analysis, melting curve analysis and denaturing-high performance liquid chromatography (dHPLC). 5 Recently, a western blot assay using polyclonal antibodies for specific identification of the mutant protein variant-A was described. 5 Furthermore, cytoplasmic nucleophosmin (NPMc) may be detected by immunohistochemistry in paraffin-embedded bone marrow (BM) trephines. [2] [3] [4] However, molecular procedures use rather sophisticated and expensive equipment and are time-consuming, whereas BM biopsies are not routinely performed for AML and take longer for decalcification and preparation. We reasoned that because of the cytoplasmic delocalization, the NPM1 protein, which is normally restricted to the nucleolus, might also be accessible for intracellular flow cytometry. The aim of this study was to develop and validate a rapid method on the basis of flow cytometric detection of NPMc as surrogate for NPM1 mutations.
To this end, fresh BM or peripheral blood samples from newly diagnosed AML patients (training set: n ¼ 215; validation set: n ¼ 83), enrolled in different German multicenter trials of the Study Alliance Leukemia, were examined by central routine leukemia diagnostics as well as flow cytometric testing for NPMc expression. BM of healthy donors and the cell lines OCI-AML3 (carrying NPM1 mutation-A) and MV4-11 (carrying the germline NPM1 gene) served as controls (Supplementary Information). To identify the optimal flow cytometric procedure for NPMc detection, five monoclonal antibodies, recognizing both mutant and wild-type NPM1 proteins, were tested (Supplementary Table S1 ). The non-conjugated NPM1 antibodies and the respective isotype controls (Abcam, Cambridge, UK) were labeled with PE (phycoerythrin) using a commercial labeling kit (Zenon; Invitrogen, Karlsruhe, Germany). Thus, all NPM1 antibodies were titrated achieving the best fluorescence signal-to-noise-ratio. A four-color immunophenotyping procedure was performed. First, the cell surface was stained with CD45FITC (fluorescein isothiocyanate; Biozol, Esching, Germany), CD34PerCP5.5 (peridinin chlorophyll 5.5) and CD117APC (allophycocyanin; BD Biosciences, San Jose, CA, USA). Second, staining with the PE-prelabeled NPM1 antibody was done using a Fix and Perm Kit (Biozol, Esching, Germany). This kit is routinely applied for the detection of cytoplasmic antigens, for example, cyCD3 or cyMPO, as well as nuclear antigens, for example, TdT. Leukemic blasts were gated on the basis of CD45 expression and side scatter. If possible, the appropriate gate setting was evaluated by backgating CD34 pos or CD117 pos events. In normal BM, CD34 and CD117 expression was mandatory for normal precursor/progenitor cell gate setting. For evaluating the NPMc expression in the non-blasts (granulo-, mono-, erythro-, lymphopoiesis) the respective cell populations were gated according to their CD45 expression and side scatter properties. The mean fluorescence intensity (MFI) of NPMc was assessed as ratio of the fluorescence intensity of NPM PE and the respective isotype control (Figure 1a ). Molecular NPM1-and FLT3-ITD mutational screening was performed in parallel, as previously described 9 ( Figure 2 ).
Of the five antibodies, the one with a sufficiently high difference in the MFI comparing the OCI-AML3 cells (with NPM1 mutation) and MV4-11 cells (with the wild-type NPM1 gene) was clone 5E3 (Supplementary Table S1), which was chosen for all further investigations. Interestingly, this was one of the two antibodies directed against the C-terminal part of the protein, which might be important for flow cytometric detection of NPMc. Normal precursor/progenitor cells of healthy BM donors showed a low NPMc expression comparable to that of MV4-11 cells. On the basis of a median MFI þ 2 standard deviations of 7.2, calculated after the analysis of progenitor cells in 23 BM donor samples, the NPMc fluorescence was defined positive in patients with a MFI48.0. This threshold was also confirmed using the Youden's Index (Table 1 and Figures 1d and e). AMLs with mutated NPM1 frequently show multi-lineage involvement (myelo-, mono-, erythro and megakaryopoiesis) 10 (Supplementary Table S2 Table S2 ). This indicates that yet unknown nucleocytoplasmic interactions might be responsible for NPM1 antibody binding in lymphocytes independent from NPM1 gene mutational status. For those reasons residual non-blasts should not serve as internal negative control for cut-off setting.
As an additional proof of the method's specificity and to control for unspecific leakage of proteins from the nucleolus due to cell damage, nucleolin, another nucleolus-restricted antigen, was stained in 50 patients in parallel (clone 4E2; Abcam, Cambridge, UK) never showing an MFI47.0. The reliability of the nucleolin staining was confirmed by the detection of nucleolin expression in patients with B-CLL 11 (Supplementary Figure S2 ). Applying these criteria to a training set and afterwards to the validation set in a blinded manner, NPMc expression was detected by flow cytometry in overall 106 AML patients (35.6%). This frequency is very similar to the proportion reported for cytoplasmically localized nucleophosmin in AML BM biopsies by immunohistochemistry (35.2%). 1 The group of NPMc pos patients showed a significantly higher median MFI compared with that in NPMc neg AML patients as well as BM donors (Table 1 and Figures 1a and b) .
When applying PCR as reference, 9 a very high overall sensitivity of the flow cytometric approach of 95.2% and specificity of 96.9% was achieved using ROC curve analysis. Thus, the separated consideration of training and validation set showed comparable results concerning sensitivity and specificity with 94.5 and 95.8%, as well as 96.9 and 100%, respectively. Preliminary results suggest that using a bulk of commercially labeled PE conjugate of the 5E3 antibody (unpublished data) might further improve these data. Sequencing of NPM1 exon 12 in NPMc pos patients showed the known predominance of type-A mutations. Furthermore, several non-type-A mutations could be discovered (Figures 1c and 2a) . After sequencing exons 9-11 in NPMc pos /wild-type exon 12 patients, two samples showed truncating abnormalities in exon 10 or 11 of NPM1, respectively (Figures 2b-d) . Searching for mutations outside exon 12 would not have been started without the flow cytometric evidence regarding NPMc expression in these cases. So far, only a few mutations outside exon 12 have been described 3 because most investigators focus on the exon 12 mutations and screening all patients over a wider area would be a tremendous effort. Therefore, flow cytometry may identify more patients with non-exon 12 mutations and allow to study the association with clinical parameters and outcome in this rare subset.
Comparison of further diagnostic features between NPMc pos and NPMc neg groups (Supplementary Table S3 ) showed the known association of NPM1c pos AML with lower CD34 expression, normal karyotype, absence of low-risk cytogenetics, 5 a high frequency of FLT3-ITD, monocytic morphology and higher blast and leukocyte counts. As a novel observation, we found a complete absence of aberrant CD2 or CD19 expression in the NPMc pos compared with the NPMc neg AML group. This is in line with the known association between aberrant CD2 and CD19 expression and low-risk cytogenetic. 12 Our data further indicate that the small subgroup of NPM1c pos AML patients with CD34 coexpression (n ¼ 20) differs from the majority of the CD34-negative NPM1-mutant patients (n ¼ 80) in several aspects. The former patients harbor more FLT3-ITD mutations (89 versus 49% of patients, Po0.01) and interestingly show a higher proportion of non-type-A NPM1 mutations, including those in exon 10 or 11 (55 versus 18%, P ¼ 0.01). This observation might indicate a different pathophysiology in these patients. It will be interesting to study whether this is related to the different distribution of NPM1 mutations in pediatric patients, which has been described in several studies. 5, 13 In addition to that, in 37.5% of CD34 neg patients (having p10% CD34 pos blasts) with NPM1 mutations, a small, but clearly separable CD34 pos subpopulation (0.1 and 5.4%) could be identified, which might include the NPMc-leukemiainitiating cells, as recently reported. Molecular analysis of these cells after sorting confirmed the presence of the NPM1 mutation.
14 Thus, the use of flow cytometry allows a more elaborate immunophenotypic characterization of patients with NPM1 mutations to better understand the pathogenesis of leukemia in this still novel subgroup of patients.
We also noted a few cases (11/298) in whom the results between flow cytometry and PCR were discrepant. The six NPMc pos patients (MFI: 8.8-31.0) without NPM1 mutation showed CD34 positivity, a wild-type FLT3 gene and only two presented with a normal karyotype. Two of those patients were Figure 2 Sequences of newly detected mutations in the NPM1 gene. Molecular NPM1-and FLT3-ITD mutational screening was performed in parallel as reported in detail previously. 9 Briefly, genomic DNA extracted from mononuclear cells taken before therapy was used for PCR with fluorescently labeled primers for exon 12 (NPM1) or exons 14 and 15 (FLT3). The obtained PCR products were subjected to high-resolution fragment analysis (Genescan) using an automated ABI-DNA sequencer (ABI3130xl; Applied Biosystems, Darmstadt, Germany). In flow cytometric Figure S3) . Sequencing of exons 9-11 did not show NPM1 mutations. In these cases, other still unrecognized interfering proteins might be responsible for the delocalization of NPM1. NPM1 gene overexpression, a well known phenomenon in solid tumors, 5 could also be discussed to contribute to the false NPMc expression. But, several previous data 3, 9 showed that NPM1 overexpression did not alter the nucleoplasmic localization of the protein. Conversely, five patients showed negative flow cytometry but an NPM1 mutation was confirmed in repetitive PCR experiments (4/5 type-A mutation) and as well the protein was seen delocalized by confocal microscopy. In these cases protein degradation or altered protein folding followed by conformational changes close to the antibody epitope could have prevented correct antibody binding before flow cytometry. The discrepancy between flow cytometry and confocal microscopy could possibly be also due to the different permeabilization and fixation protocols used for the two techniques. Remarkably, these five patients presented with high blast and leukocyte counts, were CD34 neg and all showed an aberrant CD56 expression. These findings require a confirmation in a larger patient cohort.
In summary, our results have several clinical implications. Flow cytometry offers a unique opportunity, applicable in large multicenter studies, to easily measure and correlate NPMc expression with multiple other markers and prognosis. Finally, this rapid flow cytometric screening procedure for NPMc seems to be a reliable surrogate for the presence of NPM1 mutations in AML patients and could easily be integrated in the routine immunophenotyping. The more and more complex decision trees for individualized treatment require integrated diagnostics. In this situation, a positive flow-cytometric NPMc analysis might already guide subsequent molecular and cytogenetic tests, which might help to save important resources. In addition, new treatment options for patients with NPM1 mutations, for example, the recently described treatment with all-trans retinoic acid, 8 if confirmed in other studies, require a fast screening, which might consist of a combination of NPMc flow cytometry in all patients and immediately followed by molecular mutational type screening in NPMc pos patients, only. In this regard, our simple method may serve as complementary or even as an alternative procedure to immunohistochemistry in BM biopsies for detecting cytoplasmic NPM1. This practical approach should further implement the use of the new WHO classification, which now incorporates AML with mutated NPM1. 
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